<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599429</url>
  </required_header>
  <id_info>
    <org_study_id>CIMS-2011-01</org_study_id>
    <nct_id>NCT01599429</nct_id>
  </id_info>
  <brief_title>Study of the Predictive Marker FLT in Patients Suffering From AML</brief_title>
  <acronym>TEP-FLT-LMA</acronym>
  <official_title>Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positron emission tomography uses various radioactive tracers to measure the metabolic
      activity in a none-invasive way, and specially to follow the activity of the disease during
      the treatments.

      Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool
      would allow to image and follow time wise acute myeloid leukemia (AML). The investigators
      want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic
      before and after chemotherapy treatment.

      The aim of this study is to be able to identify earlier the responders, because if they are
      detected sooner, these patients will benefit from more aggressive treatments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease.</measure>
    <time_frame>September 2015</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly diagnosed with acute myeloid, between October 2011 and October 2013, at the
        Centre Hospitalier Universitaire de Sherbrooke (CHUS).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years or above at the time of inclusion;

          2. Patients newly diagnosed with acute myeloid leukemia;

          3. No contraindication or intolerance to any of the components of the standard
             chemotherapy by induction (7+3);

          4. Patients able to give written informed consent.

        Exclusion Criteria:

          1. Patients unable to tolerate decubitus position for at least 45 minutes;

          2. Any previous neoplasia or other neoplasia simultaneously;

          3. Previously treated buy radiotherapy, with bone marrow in the field of radiation;

          4. Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before
             the second FLT-TEP was done.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Éric E Turcotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Centre d'imagerie moléculaire de Sherbrooke (CIMS), Centre de recherche Étienne Le-Bel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rami Kotb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Morin, MSc</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>16359</phone_ext>
    <email>amorin.chus@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anick Champoux, Infirmière</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12811</phone_ext>
    <email>achampoux.chus@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Morin, MSc</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>16359</phone_ext>
      <email>amorin.chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Anick Champoux, Infirmière</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12811</phone_ext>
      <email>achampoux.chus@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Hans Knecht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Castilloux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariette Lépine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice Beauregard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rami Kotb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Éric E Turcotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Dr Éric E Turcotte, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>AML / LMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

